Women—especially those in their early-to-mid-sixties and those with a heart failure diagnosis—continue to be underrepresented in cardiovascular clinical trials, according to a study that found just over 38% of all CV trial enrollees between 2010 and 2017 were female.
A wearable sensor developed by researchers at University of Utah Health and VA Salt Lake City Health Care System has the potential to predict heart failure complications more than a week before they occur.
Three-year data from the BIOFLOW-V trial, presented Feb. 23 at the 2020 CRT Congress in National Harbor, Md., reinforce the status of Biotronik’s Orsiro drug-eluting stent as superior to the popular Xience stent.
A study published Feb. 25 in Circulation suggests wearables are useful for detecting CV abnormalities like atrial fibrillation, but there’s still a long way to go before they can be trusted for clinical management.
Brain stents seem to be safe and effective in reducing the risk of recurrent stroke in patients who suffer from cholesterol-clogged brain arteries, according to research presented at the American Stroke Association’s International Stroke Conference.
Digital healthcare tools and apps can be more beneficial than risky if they’re used responsibly, according to a perspective published in Circulation on Feb. 24.
The diabetes drug dulaglutide—sold commercially as Trulicity—has received an expanded indication for the reduction of major adverse cardiovascular events in adults with type 2 diabetes and established CVD or CV risk factors.
Presidential hopeful Bernie Sanders has refused to release further medical information about an MI he suffered last October, leaving much of the public with questions about his heart health.
Mount Sinai has launched an Adult Congenital Heart Disease Center at Mount Sinai Heart in New York in an attempt to streamline CHD care throughout the life cycle.
